In a public filing, medical device maker Covidien recently revealed that it recorded a $180 million charge in its third quarter for lawsuits over dangerous pelvic mesh products. Covidien supplied transvaginal mesh products to a manufacturer being sued for serious side effects including abdominal inflammation, bleeding, extrusions, infections, bladder perforation, scarring, pain, and recurrence of pelvic organ prolapse and stress urinary incontinence that the device was supposed to treat.
Covidien made, sold, and marketed several transvaginal mesh products under the name Duo and formerly as Tyco Healthcare, including:
- IVS Tunneler Intra-Vaginal Sling
- IVS Tunneler Placement Device
- Parietene Polypropylene Mesh
- Surgipro Polyproylene Surgical Mesh
- Pelvicol Mesh
- Mentor ObTape
Women nationwide have filed lawsuits against Covidien from complications related to vaginal mesh products. A Texas woman sued after she needed multiple revision surgeries due to experiencing severe side effects from Covidien’s Pelgicol mesh implant. She charged Covidien with breach of warranty, a failure to warn consumers of side effects, and for negligence.
In a filing with the Securities and Exchange Commission, Covidien said there are more than 5,600 cases pending related to its transvaginal mesh products. Covidien said it made the decision to record a pre-tax charge of approximately $180 million in light of discussions with trial lawyers and settlements by other transvaginal mesh product makers. In April, Endo International paid $830 million to resolve claims by women who filed transvaginal mesh lawsuits.
Two subsidiaries of Covidien supplied pelvic mesh implant products to a manufacturer named in a federal multi-district litigation and Covidien is indemnifying that manufacturer.
At The Cochran Firm, D.C., our team of experienced trial attorneys are accepting claims nationwide related to transvaginal mesh injuries. If you or someone you love was injured by one of these products, please contact us at 202-682-5800 to receive a free case evaluation.